|
Volume
24 Number 21
15 November 2022
|
|
Home
>
Publications
>
Neuro-Oncology
Reviews >
Volume
24, Year 2022 >
Number 21, 15 November
|
|
|
|
|
|
Aiyappa-Maudsley R, Chalmers AJ, Parsons JL.
Factors
affecting the radiation response in glioblastoma.
Neurooncol
Adv. 2022 Sep 25, 2022;4(1):vdac156→.
doi: 10.1093/noajnl/vdac156→.
PMID: 36325371→.
Review. →
|
|
|
|
Fougner V, Hasselbalch B, Lassen U, Weischenfeldt J, Poulsen HS,
Urup T.
Implementing targeted
therapies in the treatment of glioblastoma: Previous shortcomings,
future promises, and a multimodal strategy
recommendation.
Neurooncol
Adv. 2022 Sep 28, 2022;4(1):vdac157→.
doi: 10.1093/noajnl/vdac157→.
PMID: 36325372→.
Review. →
|
|
|
|
Miller R, Niazi M, Russial O, Poiset S, Shi W.
Tumor
treating fields with radiation for glioblastoma: a narrative
review.
Chin
Clin Oncol. 2022 Oct;11(5):40→.
doi: 10.21037/cco-22-90→.
PMID: 36336899→.
Review. →
|
|
|
|
Mahmoud AB, Ajina R, Aref S, Darwish M, Alsayb M, Taher M,
AlSharif SA, Hashem AM, Alkayyal AA.
Advances
in immunotherapy for glioblastoma multiforme.
Front
Immunol. 2022 Oct 12, 2022;13:944452→.
doi: 10.3389/fimmu.2022.944452→.
PMID: 36311781→.
Review.
|
|
|
|
Marabitti V, Giansanti M, De Mitri F, Gatto F, Mastronuzzi A,
Nazio F.
Pathological implications
of metabolic reprogramming and its therapeutic potential in
medulloblastoma.
Front
Cell Dev Biol. 2022 Oct 19, 2022;10:1007641→.
doi: 10.3389/fcell.2022.1007641→.
PMID: 36340043→.
Review. →
|
|
|
|
Andersen BM, Reardon DA.
Immunotherapy
approaches for adult glioma: knowledge gained from recent clinical
trials.
Curr
Opin Neurol. 2022 Oct 21, 2022;35(6):803-813→.
doi: 10.1097/WCO.0000000000001118→.
PMID: 36367046→.
Review˰ →
|
|
|
*
|
Jovanovich N, Habib A, Head J, Anthony A, Edwards L, Zinn
PO.
Opinion: Bridging gaps and
doubts in glioblastoma cell-of-origin.
Front
Oncol. 2022 Oct 21, 2022;12:1002933→.
doi: 10.3389/fonc.2022.1002933→.
PMID: 36338762→.
Opinion. →
|
|
|
|
Mallick S, Benson R, Venkatesulu B, Melgandi W, Rath
GK.
Systematic Review and Individual
Patient Data Analysis of Uncommon Variants of Glioblastoma: An
Analysis of 196 Cases.
Neurol
India. 2022 Oct 21, 2022;70(5):2086-2092→.
doi: 10.4103/0028-3886.359222→.
PMID: 36352613→.
Review. →
|
|
|
|
Lehrer EJ, Kowalchuk RO, Ruiz-Garcia H, Merrell KW, Brown PD,
Palmer JD, Burri SH, Sheehan JP, Quninoes-Hinojosa A, Trifiletti
DM.
Preoperative stereotactic
radiosurgery in the management of brain metastases and
gliomas.
Front
Surg. 2022 Oct 24, 2022;9:972727→.
doi: 10.3389/fsurg.2022.972727→.
PMID: 36353610→.
Review. →
|
|
|
|
Ling SP, Ming LC, Dhaliwal JS, Gupta M, Ardianto C, Goh KW,
Hussain Z, Shafqat N.
Role of
Immunotherapy in the Treatment of Cancer: A Systematic
Review.
Cancers
(Basel). 2022 Oct 24, 2022;14(21):5205→.
doi: 10.3390/cancers14215205→.
PMID: 36358624→.
Review. →
|
|
|
|
Lim YJ.
Medical Treatment of
Pediatric Low-Grade Glioma.
Brain
Tumor Res Treat. 2022 Oct 27, 2022;10(4):221-225→.
doi: 10.14791/btrt.2022.0039→.
PMID: 36347636→.
Review. →
|
|
|
|
Schirrmacher V, van Gool S, Stuecker W.
Counteracting
Immunosuppression in the Tumor Microenvironment by Oncolytic
Newcastle Disease Virus and Cellular Immunotherapy.
Int
J Mol Sci. 2022 Oct 27, 2022;23(21):13050→.
doi: 10.3390/ijms232113050→.
PMID: 36361831→.
Review. →
|
|
|
|
Luo Y, Tian G, Fang X, Bai S, Yuan G, Pan Y.
Ferroptosis
and Its Potential Role in Glioma: From Molecular Mechanisms to
Therapeutic Opportunities.
Antioxidants
(Basel). 2022 Oct 28, 2022;11(11):2123→.
doi: 10.3390/antiox11112123→.
PMID: 36358495→.
Review. →
|
|
|
|
Catalano M, Serpe C, Limatola C.
Microglial
Extracellular Vesicles as Modulators of Brain Microenvironment in
Glioma.
Int
J Mol Sci. 2022 Oct 29, 2022;23(21):13165→.
doi: 10.3390/ijms232113165→.
PMID: 36361947→.
Review. →
|
|
|
|
Foo CY, Munir N, Kumaria A, Akhtar Q, Bullock CJ, Narayanan A, Fu
RZ.
Medical Device Advances in the
Treatment of Glioblastoma.
Cancers
(Basel). 2022 Oct 29, 2022;14(21):5341→.
doi: 10.3390/cancers14215341→.
PMID: 36358762→.
Review. →
|
|
|
|
Goldman M, Lucke-Wold B, Martinez-Sosa M, Katz J, Mehkri Y,
Valisno J, Quintin S.
Steroid
utility, immunotherapy, and brain tumor management: an update on
conflicting therapies.
Explor
Target Antitumor Ther. 2022 Oct 31, 2022;3(5):659-675→.
doi: 10.37349/etat.2022.00106→.
PMID: 36338521→.
Review. →
|
|
|
|
Szklener K, Mazurek M, Wieteska M, Wacławska M, Bilski M,
Mańdziuk S.
New Directions in
the Therapy of Glioblastoma.
Cancers
(Basel). 2022 Oct 31, 2022;14(21):5377→.
doi: 10.3390/cancers14215377→.
PMID: 36358795→.
Review. →
|
|
|
|
|
|
Onishi S, Ohba S, Kuraoka K, Kurashige T, Sugiyama K, Yamasaki
F.
Molecular and clinical
characterization of H3 K27M-mutant "non-midline"
glioblastoma: A case report and literature review.
Neurocirugia
(Astur:Engl Ed). 2022 Nov 1, 2022;33(6):356-360→.
doi: 10.1016/j.neucie.2021.06.008→.
PMID: 36333093→.
Case report, Review˰ →
|
|
|
|
Wu L, Chai R, Zhao Z, Wang Q, Jiang T.
Role
of the tumor microenvironment in shaping IDH-wildtype glioma
plasticity, and potential therapeutic strategies.
Cancer
Biol Med. 2022 Nov 1, 2022;19(10):1423–7→.
doi: 10.20892/j.issn.2095-3941.2022.0363→.
PMID: 36350003→.
Editorial. →
|
|
|
|
Haddad AF, Aghi MK, Butowski N.
Novel
intraoperative strategies for enhancing tumor control: Future
directions.
Neuro
Oncol. 2022 Nov 2, 2022;24(S6):S25-S32→.
doi: 10.1093/neuonc/noac090→.
PMID: 36322096→.
Review.
→
|
|
|
|
Odia Y, Gutierrez AN, Kotecha R.
Stereotactic
targeted radiation therapy (STaRT) trials for brain neoplasms: A
comprehensive review. [GammaTile®]
Neuro
Oncol. 2022 Nov 2, 2022;24(S6):S16-S24→.
doi: 10.1093/neuonc/noac130→.
PMID: 36322100→.
Review. →
|
|
|
|
Schupper AJ, Chanenchuk T, Racanelli A, Price G, Hadjipanayis
CG.
Laser
hyperthermia: Past, present, and future. [LITT]
Neuro
Oncol. 2022 Nov 2, 2022;24(S6):S42-S51→.
doi: 10.1093/neuonc/noac208→.
PMID: 36322099→.
Review. →
|
|
|
|
Wu A, Wu JY, Lim M.
Updates in
intraoperative strategies for enhancing intra-axial brain tumor
control.
Neuro Oncol. 2022 Nov 2,
2022;24(S6):S33-S41→.
doi: 10.1093/neuonc/noac170→.
PMID: 36322098→.
Review. →
|
|
|
|
Bahadur S, Prakash A.
A
Comprehensive Review on Nanomedicine: Promising approach for
treatment of brain tumor through intranasal administration.
Curr
Drug Targets. 2022 Nov 3→.
doi: 10.2174/1389450124666221019141044→.
PMID: 36278468→.
Review˰ →
|
|
|
|
Khristov V, Lin A, Freedman Z, Staub J, Shenoy G, Mrowczynski O,
Rizk E, Zacharia B, Connor J.
Tumor-derived
Biomarkers in Liquid Biopsy of Glioblastoma.
World
Neurosurg. 2022 Nov 5, 2022:S1878-8750(22)01554-6→.
doi: 10.1016/j.wneu.2022.11.012→.
PMID: 36347463→.
Review˰ →
|
|
|
|
Seliger C, Oppong FB, Lefranc F, Chinot O, Stupp R, Nabors B,
Gorlia T, Weller M; EORTC Brain Tumor Group.
Research
Article: Association of antidepressant drug use with outcome of
patients with glioblastoma.
Int
J Cancer. 2022 Nov 8→.
doi: 10.1002/ijc.34344→.
PMID: 36346112→.
Pooled analysis. →
|
|
|
|
Adnani L, Spinelli C, Tawil N, Rak J.
Role
of extracellular vesicles in cancer-specific interactions between
tumour cells and the vasculature.
Semin
Cancer Biol. 2022 Nov 9, 2022:S1044-579X(22)00225-5→.
doi: 10.1016/j.semcancer.2022.11.003→.
PMID: 36371024→.
Review˰ →
|
|
|
|
Oztek MA, Noda SM, Romberg EK, Cole BL, Wright JN, Ishak GE, Perez
FA.
Changes to pediatric brain
tumors in 2021 World Health Organization classification of tumors
of the central nervous system.
Pediatr
Radiol. 2022 Nov 9→.
doi: 10.1007/s00247-022-05546-w→.
PMID: 36348014→.
Review˰ →
|
|
|
|
Chidley P, Shanker M, Phillips C, Haghighi N, Pinkham MB, Whittle
JR, Sia J.
Moderately
hypofractionated versus conventionally fractionated radiation
therapy with temozolomide for young and fit patients with
glioblastoma: an institutional experience and meta-analysis of
literature.
J
Neurooncol. 2022 Nov 10, 2022:1–14→.
doi: 10.1007/s11060-022-04151-z→.
PMID: 36355260→.
Observational study, Meta-analysis. →
|
|
|
|
Yang Y, Schubert MC, Kuner T, Wick W, Winkler F, Venkataramani
V.
Brain Tumor Networks in Diffuse
Glioma.
Neurotherapeutics.
2022 Nov 10→.
doi: 10.1007/s13311-022-01320-w→.
PMID: 36357661→.
Review. →
|
|
|
|
Kizilbash SH.
Why has targeting EGFR
aberrations in glioblastoma therapy had limited success?
Expert
Rev Anticancer Ther. 2022 Nov 11→.
doi: 10.1080/14737140.2022.2146581→.
PMID: 36367033→.
Editorial. →
|
|
|
|
|
|
|
|
|
